Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2024 · 10-Q
Revenue$12.04M$12.04M+9.0% vs Q2 2023 Net Income$2.44M$2.44M+336.0% vs Q2 2023 EPS Diluted$0.55$0.55+323.1% vs Q2 2023 Gross Profit$7,806,000+8.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,404,000+241.6% Free Cash Flowderived$1,207,000+302.3% Margins · derivedGross margin64.8%−0.5 pt vs Q2 2023
Operating margin21.9%+10.8 pt vs Q2 2023
Net margin20.2%+15.2 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end